The CMA has prevented part of a merger between two of the biggest players in the UK’s hearing implant sector. This action will avoid worse outcomes for patients, who rely on these life-changing hearing implants, and higher prices for the NHS, which ultimately funds the cost of these products for patients.
The investigation has found that the merger may lead to a substantial lessening of competition in bone conduction solution products. These products are implants that bypass the damaged parts of the ear, converting sounds into vibrations that are sent directly to the inner ear.
DT Economics managing partner, David Thomas, was a member of the independent inquiry group.
Further details on the CMA's case page: